

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
MPIP:101US

In Re Application Of: Cun ZHUANG, Hirokazu KAWAGISHI and Harry G. PREUSS

Serial No.
10/762,927

Filing Date
01/22/2004

Examiner
N/A

Group Art Unit
1614

Title: **GLYCOPROTEIN WITH ANTIDIABETIC, ANTIHYPERTENSIVE, ANTI OBESITY AND
ANTHYPERLIPIDEMIC EFFECTS FROM GRIFOLA FRONDOSA, AND A METHOD FOR PREPARING SAME**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
MPIP:101US

In Re Application: Cun ZHUANG, Hirokazu KAWAGISHI and Harry G. PREUSS

Serial No.
10/762,927Filing Date
01/22/2004Examiner
N/AGroup Art Unit
1614**GLYCOPROTEIN WITH ANTIDIABETIC, ANTIHYPERTENSIVE, ANTI OBESITY AND
ANTHYPERLIPIDEMIC EFFECTS FROM GRIFOLA FRONDOSA, AND A METHOD FOR PREPARING****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account 50-0822
as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*I certify that this document and authorization to charge deposit
account is being facsimile transmitted to the United States Patent
and Trademark Office (Fax. No. _____) on _____

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class MailI certify that this document and fee is being deposited on
May 4, 2004 with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to
the Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

S. Peter Konzel, Esq.

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by
deposit account.**

Dated: May 4, 2004


Signature
S. Peter Konzel, Esq.
Registration No. 53,152
CUSTOMER NO. 24041
Simpson & Simpson, PLLC
5555 Main Street
Williamsville, NY 14221-5406
Telephone No. 716-626-1564
CRL/KRB

CC:

(Use several sheets if necessary)

MAY 07 2004

MPDP:101US

10/762.927

APPLICANT(S)
Zhuang et al.

01/22/2004

1614

[illegible][illegible]


		<p>Keiko Kubo, Hisao Aoki, and Hiroaki Nanba. "Anti-diabetic Activity Present in the Fruit Body of <i>Grifola frondosa</i> (Maitake). I", <i>Biol. Pharm. Bull.</i>, Vol. 17, No. 8, 1994, pp. 1106-1110.</p> <p>Hirotsada Kurushima, Noriko Kodama and Hiroaki Nanba. "Activities of polysaccharides obtained from <i>Grifola frondosa</i> on insulin-dependent diabetes mellitus induced by streptozotocin in mice", <i>Mycoscience</i>, Vol. 41, 2000, pp. 473-480.</p>
		<p>Keiko Kubo and Hitoaki Nanba. "Anti-Diabetic Mechanism of Maitake (<i>Grifola frondosa</i>)", <i>Penn. State Univ.</i>, 1996, pp. 215-221.</p> <p>Manohar V., Talpur N.A., Echard B.W. Lieberman S. and Preuss H.G. "Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice", <i>Diabetes, Obesity and Metabolism</i>, Vol. 4, 2002, pp. 43-48.</p>

DATE CONSIDERED

PAGE 1 OF 2

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.

MPIP:101US

SERIAL NO.

10/762,927

APPLICANT(S)

Zhuang et al.

FILING DATE

01/22/2004

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Talpur N.A., Echard B.W., Fan A.Y., Jaffari O., Bagchi D. and Preuss H.G. "Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains", Molecular and Cellular Biochemistry, Vol. 237, 2002, pp. 129-136.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.